Astellas makes changes to management structure

Will dissolve the positions of QA and RA Head at Astellas Pharma

Japanese pharmaceutical firm Astellas has made changes to its management structure that aim to improve global product compliance and streamline global drug development.

From 1 April, all Heads of Global Development, Global Regulatory Affairs, Global Clinical Research Quality Assurance and Global Quality Assurance will report to the Chief Medical Officer. As a result, the positions of QA and RA Head of Astellas Pharma will cease to exist.